Related Experiment Videos
Hepatitis B genotypes and the response to interferon therapy.
1Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei.
Journal of Hepatology
|December 29, 2000
Summary
Hepatitis B virus (HBV) genotype C patients show a lower response rate to interferon alfa therapy compared to genotype B. Genotype C is also linked to higher core promoter mutations, impacting treatment efficacy.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis B virus (HBV) genotypes may exhibit pathogenic differences.
- The impact of HBV genotype on interferon therapy response is not well understood.
Purpose of the Study:
- To investigate the efficacy of interferon alfa in treating chronic hepatitis B patients across different HBV genotypes.
- To determine if HBV genotype influences the response to interferon therapy.
Main Methods:
- Retrospective study of 58 chronic hepatitis B patients treated with interferon alfa-2b.
- Patients were infected with either HBV genotype B or C.
- Treatment response was defined by normalization of aminotransferase levels, HBeAg loss, and undetectable HBV DNA at 48 weeks post-treatment.
Main Results:
- Genotype C patients had higher baseline serum aminotransferase levels and core promoter mutations.
- The response rate to interferon alfa was significantly lower in genotype C patients (15%) compared to genotype B patients (41%).
- Higher baseline aminotransferase levels and genotype B infection were associated with a better treatment response.
Conclusions:
- HBV genotype C is associated with a higher frequency of core promoter mutations.
- HBV genotype C demonstrates a lower response rate to interferon alfa therapy compared to genotype B.
- Younger age and genotype B infection may predict a favorable response to interferon alfa treatment.